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OF PREMATURE OVARIAN INSUFFICIENCY
Premature ovarian failure (POF) is a  term  usually used to describe women younger 
than 40 years o f  age w ho present with amenorrhea. Diagnosis o f  POF is on the basis o f 
follicle stimulating hormone level in the menopausal range associated with amenorrhea 
before the age o f 40. W om en diagnosed with the POF suffered from anovulation and 
hypoestrogenism and presented with primary or secondary' amenorrhea, infertility, sex 
steroid deficiency, and elevated gonadotrophins [1, p. 245] POF is the causative factor in 
10 28 % o f  wom en presenting with am enonhea and in 4 18 %  with secondary 
amenorrhea [2, p. 236; 3, p. 45]. The course o f  POF is poorly defined [4, p. 112]. Perhaps 
50 % o f  spontaneously affected woman have the evidence o f  follicular activity and 
probably 25 %  ovulate even before the diagnosis is established. Some o f  these women 
even conceive. It is increasingly felt that it may be appropriate to refer to them  as patients 
with «primary ovarian insufficiency.» The term  primary ovarian insufficiency (POI) 
originally suggested by Albright appropriately describes a continuation o f  impaired 
ovarian function and is also less stigmatizing than the terms used previously [5, p. 38]. 
Two mechanisms are probably involved in POL namely follicle dysfunction and follicle 
depletion [6, p. 253]. The existing follicles in the ovary, in  follicle dysfunction, do not 
function normally due to some pathological process such as for e.g. FSIT receptor 
mutation [7, p. 86J. O n the oilier hand, in women with follicle depletion there are no 
primordial follicles probably due to inadequate initial pool o f primordial follicles or 
destruction o f  follicles due to toxins or autoimmune mechanisms ]5, p. 39]. Lhe primary 
goal o f the scientists working in this area should be to focus on the etiology o f  lA)! [8, p. 
99]. Some o f  the causes can lead to complete absence o f  oocytes, and others can lead to 
inability o f  follicles to mature or to disordered folliculogenesis. The causes could be 
chromosomal, genetic, autoimmune, metabolic (galactosemia), infection (mumps), 
and iatrogenic [9, p. 123]. A m ong the several m echanism s that account for the 
pathogenesis o f  spontaneous POL genetic and autoim m une m echanism s play a m ajor 
role. X  chrom osom e abnorm alities have been system atically review ed by Persani ct 
al [10, p. 96]. N om ial ovarian function requires two functioning X chrom osom es. In 
the Turner Syndrome, there is a  com plete loss o f the second chrom osom e resulting in
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the m ost severe and  irreversible P O l often  clinically evident prior to  m enarche 
[11, p. 176]. Prevalence o f  other genetic defects causing P O I has been difficult to 
determine. G ene for blepharophim osis/ptosis/PO I syndrom e has been recently 
reported but has not been seen com m only in patients w ith POl. O f the various knock 
out m ice m odels created with deficient ovarian function, the m ost interesting one is a 
heterozy gous FSH  receptor knock out m ouse, w hich has exhibited a reduced follicle 
reserve and early ovarian depletion [11, p. 29]. hi this review , w e will focus on the 
role o f  autoim m unity in  the pathophysiology o f  POI. The hum an ovary can be a 
target for an  autoim m une attack under various circumstances. C linically, the ensuing 
ovarian dysfunction often results in prem ature ovarian insufficiency characterized by 
am enorrhea lasting 4 6 m onths and is classically defined as secondary am enorrhea 
accom panied by a hypergonadotropic—hypoestrogenic condition before die age o f  40 
years [12, p. 49]. It has long been recognized that POI could be associated with 
nearly all organ specific and  non- organ- specific autoim m une diseases, and  its 
association w ith  the endocrine glands such as the thyroid, pancreas, and adrenal 
glands has been reported [13, p. 68]. Vallotlon and Forbes [ 14, p.66] w ere the first to 
describe the presence o f  antibodies to rabbit ova cytoplasm  using sera from POI 
patients. A utoim m une PO I (A l POI) is characterized by organ specific targeting o f  
the im m une response accom panied by tissue destruction, w hich can have w idespread 
systemic com plications in severe cases. The disease affects 1 %  o f  the general 
population [15, p. 78 1). There could be several reasons for the differences am ong the 
study results. First, study design elem ents, such as antibody test form at and antigen 
preparation and criteria for study and com parison groups differ. Second, there may be 
several antigenic targets, and often only one m ay have been assessed. M oncayo et al 
[19, p. 581. developed an  ELISA using m icrosom es from  bovine corpora lutea as the 
antigen. Luborsky e t al [17, p. 39]. developed an ELISA  kit using total human 
ovary /oocytes as antigen and showed that sera from  71 %  o f  w om en w ith POF in 
their study had antibodies either to w hole ovary or to oocytes.
We also propose that the AOA test should be a part o f the battery o f  tests 
included for infertility treatm ent and managem ent. Very little is know n about the 
precise nature o f  the ovarian antigens that are recognized by the antibodies in sera. 
Antigens o f  oocyte, [14, p. 238) corpus luteum  [17, p. 69], granulosa cells 116, p. 
128], and ZP [21, p. 62] have been reported to act as autoantigens; how ever, their 
m olecular identity and pathophysiologic significance rem ain obscure. The oocyte 
seems to be the m ost often targeted cell o f  A O A  detected in cases o f  ovarian diseases 
as w ell as in  wom en w ith poor assisted reproductive technologies (ART) outcom es 
[22, p. 89]. A  thorough literature review  on  infertility with autoim m une involvem ent 
has indicated that very few proteins have been form ally identified and characterized
using sera o f  wom en with infertility [28, p. 146]. One report dem onstrated 
autoantibodies to a enolase, [30, p. 66] and several reports have show n the presence 
o f  circulating antibodies directed tow ard different ovarian structures [16, p. 49; 17, p. 
57; 22, p. 86] Identification and system atic characterization o f  target antigens are the 
prerequisites for elucidation o f  the underlying im m unologic m echanism s and also for 
devising better approaches for the diagnosis and treatm ent o f  P O I leading to 
infertility 136, p. 89]. ( >nce their identity has been established, they could be used for 
sim ple, noninvasive diagnostic tests to screen large populations o f  women with 
infertility or repeated im plantation failures as well as to screen patients before and 
after enrollm ent in an IVF ET program.
A lthough a num ber o f  tests have been developed to detect these antibodies, 
neither their specificity nor their diagnostic relevance has been established.
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